Alliance Global downgraded Aptose Biosciences (APTOF) to Neutral from Buy with a C$2.41 price target The firm does not expect better offer than the Hanmi tender.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APTOF:
- Aptose Biosciences to be Acquired by Hanmi Pharmaceutical
- Aptose Biosciences Reports Financial Challenges in Q3 2025
- Aptose Biosciences Reports Promising Results in AML Therapy Trials
- Aptose Biosciences’ TUSCANY Study Highlighted at ASH 2025
- Aptose Biosciences’ Tuspetinib Study: A Potential Game-Changer in Leukemia Treatment